PMC10203499_01
White blood cell, hemoglobin, and platelet counts for a young Chinese patient with SLE and schedule of treatment. WBC: white blood cells; NEU: neutrophils; LYM: lymphocytes; RBC: red blood cells; HGB: hemoglobin; RIM: rheumatic immunology department. AZA: azathioprine tablet; Rh-GCSF: recombinant human granulocyte colony stimulating factor injection; Methylprednisolone: methylprednisolone sodium succinate for injection; Immunoglobulin: human immunoglobulin for intravenous injection; Folic: folic acid tablets; Piperacillin and sulbactam: piperacillin sodium and sulbactam sodium for injection; Meropenem: meropenem for injection; Azithromycin: azithromycin for injection; Vancomycin: vancomycin for injection; Voriconazole: voriconazole for injection; Famciclovir: famciclovir dispersible tablets.
fphar-14-1001559-g001.jpg
PMC10203499_01_fphar-14-1001559-g001.jpg
F1
During discontinuation, the patient was given folic acid (10 mg TID p.o.) to compete with AZA for hypoxanthine binding; recombinant human granulocyte colony-stimulating factor (150 mug QD~300 mug BID i.h.); recombinant human thrombopoietin injection (15,000 U QD i.h.) to increase leucocyte and platelet counts; methylprednisolone to reduce inflammation; and meropenem, vancomycin, voriconzole, and famciclovir to treat infections (Figure 1).